Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. SPCX
10. SPY

Go back to Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

February 10, 2025 4:01 PM EST

Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023

Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion

ALYFTREK approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX approved in the U.S. for moderate-to-severe acute pain

Diverse late-stage clinical pipeline accelerates with four programs in pivotal development

Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating... More